Puerperal Disorders: Clinical Trials

78 trials for Puerperal Disorders, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

46 completed, 14 unknown, 7 recruiting, 3 active not recruiting. 78 Phase 3, 14 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 378Completed 46, Unknown 14, Recruiting 7, Active not recruiting 3, Not yet recruiting 3, Withdrawn 3, Terminated 2
Phase 214Completed 8, Active not recruiting 2, Unknown 2, Terminated 1, Withdrawn 1

Follow Puerperal Disorders: new trials by email Literature Review of Puerperal Disorders trials Research Report on Puerperal Disorders

Trials (filtered) newest first · largest first

All 78 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Brexanolone Lifting Outcomes Of Moms
LPCN 1154A, Placebo - Depression, Postpartum, Postpartum Depression (PPD)
Phase 3RecruitingLipocine Inc.1202026-09-012026-09-16
A Study of MI078 for Postpartum Depression
MI078 capsule, Placebo of MI078 capsules - Postpartum Depression (PPD)
Phase 3RecruitingNanjing Minova Pharmaceutical Co., Ltd.2002026-07-102026-07-23
The PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity
Aspirin, Low-molecular-weight heparin - Venous Thromboembolism, Postpartum Period
Phase 3RecruitingUniversity of Calgary88052026-06-042026-07-27
Investigating the Efficacy of Tranexamic Acid as a Prophylactic Agent in Reducing Postpartum Hemorrhage Among Patients Undergoing Cesarean Section in SQUH
tranexamic acid (1 g diluted in 100 mL of 0.9% saline, Normal (0.9%) saline - Post Partum Haemorrhage
Phase 3Not yet recruitingSultan Qaboos University882026-05-012026-04-01
EVE TRIAL , ALMA SYSTAM
Alma System - Postpartum Haemorrhage (PPH), PPH
Phase 3RecruitingResQ Medical Ltd502026-01-112026-03-30
The Perinatal Synergistic Multi-component Intervention to alLeviate dEpressive Symptoms. A Case Series
interpersonal psychotherapy (IPT), Ketamine - Postpartum Depression
Phase 2 / Phase 3WithdrawnWashington University School of Medicine2025-10-152025-10-29
A Study to Assess the Safety and Efficacy of Oral LPCN 1154A in Women With Severe PPD
LPCN 1154A, Placebo - Depression, Postpartum, Depression, Post-Partum
Phase 3CompletedLipocine Inc.902025-06-162026-02-24
Double Simultaneous Uterotonic Agents Versus Single Agent Regimen to Prevent Early Postpartum Hemorrhage
Sublingual Misoprostol, IV Oxytocin - Postpartum Hemorrhage
Phase 3RecruitingStony Brook University13582025-01-272025-05-04
Comparison Between Preoperative Vaginal and Postoperative Sublingual Misoprostol for Prevention of Postpartum Hemorrhage During Cesarean Section
Misoprostol - Postpartum Hemorrhage
Phase 3Not yet recruitingAssiut University4002025-01-012025-01-09
Prophylactic Amnioinfusion for Prevention of Postpartum Hemorrhage
Saline delivered using an intrauterine pressure catheter (IUPC) - Postpartum Hemorrhage
Phase 3Not yet recruitingThe University of Texas Health Science Center, Houston7002024-11-112024-11-18
Comparing Intramyometrial Tranexamic Acid and Oxytocin for Blood Loss in Cesarean Section
Tranexamic acid injection, Oxytocin - Cesarean Section Complications, Tranexamic Acid
Phase 3UnknownCairo University1502024-10-012024-09-05
Tranexamic Acid to Prevent Heavy Bleeding After Childbirth in Women At Higher Risk
Tranexamic acid, Placebo - Postpartum Hemorrhage
Phase 3RecruitingLondon School of Hygiene and Tropical Medicine300002024-04-222025-03-11
Tranexamic Acid for the Prevention of Postpartum Hemorrhage in Pregnant Women With Placenta Previa
Tranexamic acid, 0.9% sodium chloride - Hemorrhage, Postpartum, Placenta Previa
Phase 3CompletedGuangzhou Medical University17322023-07-122025-03-27
Resources, Inspiration, Support and Empowerment (RISE) for Black Pregnant Women
MWSH plus Candlelit Care, MWSH - Pregnancy Related, Pregnancy Complications
Phase 2 / Phase 3Active not recruitingCedars-Sinai Medical Center1502023-06-012026-10-22
mHealth Mindfulness Intervention for Pregnant Black and Latina Women at Risk of Postpartum Depression
Stress reduction program 'A', Stress reduction program 'B' - Post Partum Depression, Perinatal Depression
Phase 3Active not recruitingKaiser Permanente6002022-06-142025-08-05
Calcium Chloride for Prevention of Blood Loss During Intrapartum Cesarean Delivery
Calcium chloride, Saline placebo - Uterine Atony, Uterine Atony With Hemorrhage
Phase 3CompletedStanford University1202022-04-042024-06-11
Prevent Postpartum Hemorrhage in Women With Von Willebrand Disease: The VWD-WOMAN Trial
Recombinant Von Willebrand factor, Tranexamic Acid Injection [Cyklokapron] - Von Willebrand Diseases, Postpartum Hemorrhage
Phase 3CompletedNicoletta C Machin202021-06-042025-10-31
The Efficacy of Tranexamic Acid in Preventing Postpartum Haemorrhage After Caesarean Section
Tranexamic acid injection, Normal saline placebo - Postpartum Hemorrhage
Phase 3CompletedUniversity of Zimbabwe12262021-03-232023-03-20
Ketamine to Prevent PPD After Cesarean
Ketamine 50 MG/ML, Control - Postpartum Depression
Phase 3CompletedWashington University School of Medicine252020-11-122023-01-26
Sublingual vs Intrauterine MISOPROSTOL Plus Oxytocin Infusion for Prevention of Post-cesarean Hemorrhage in High Risk Pregnant Women: A Double-blind Placebo RCT
sublingual Misoprostol, Intrauterine Misoprostol - To Compare Efficacy Intrauterine vs Sublingual MISOPROSTOL in Addition to Oxytocin in Reducing Blood Loss of Post-cesarean Section in High Risk Women
Phase 3CompletedDepartment of Medical Services Ministry of Public Health of Thailand1352020-10-302021-09-13

Showing 20 of 78. Sign in to see all of them.

Narrower conditions

Postpartum Hemorrhage (52)  ·  Depression, Postpartum (21)  ·  Depression (4)  ·  Hemorrhage (4)  ·  Placenta Previa (3)  ·  Puerperal Infection (3)  ·  Anemia (2)  ·  Breast Feeding (2)  ·  Neonatal Sepsis (2)  ·  Pre-Eclampsia (2)  ·  Uterine Inertia (2)  ·  Agnosia (1)  ·  Anemia, Iron-Deficiency (1)  ·  Anxiety Disorders (1)

Broader conditions

Female Urogenital Diseases and Pregnancy Complications (78)  ·  Urogenital Diseases (78)  ·  Pregnancy Complications (77)  ·  Pathological Conditions, Signs and Symptoms (58)  ·  Pathologic Processes (56)  ·  Obstetric Labor Complications (52)  ·  Uterine Hemorrhage (52)  ·  Hemorrhage (48)  ·  Depressive Disorder (21)  ·  Mental Disorders (21)  ·  Mood Disorders (21)  ·  Behavior (7)  ·  Hematologic Diseases (5)  ·  Hemic and Lymphatic Diseases (5)

Interventions

Tranexamic Acid (18)  ·  Oxytocin (17)  ·  Misoprostol (11)  ·  Sodium Chloride (9)  ·  carbetocin (6)  ·  brexanolone (5)  ·  Saline Solution (3)  ·  Ergonovine (2)  ·  Ketamine (2)  ·  iron isomaltoside 1000 (2)  ·  zuranolone (2)  ·  Amoxicillin (1)  ·  Aripiprazole (1)  ·  Aspirin (1)  ·  Azithromycin (1)

Sponsors

Ain Shams University (4)  ·  Cairo University (4)  ·  London School of Hygiene and Tropical Medicine (3)  ·  Supernus Pharmaceuticals, Inc. (3)  ·  Assiut University (2)  ·  Azienda U.S.L. 1 di Massa e Carrara (2)  ·  Biogen (2)  ·  Gynuity Health Projects (2)  ·  KK Women's and Children's Hospital (2)  ·  Lipocine Inc. (2)  ·  London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (2)  ·  Pharmacosmos A/S (2)  ·  Stanford University (2)  ·  University Hospital, Bordeaux (2)  ·  University of Pittsburgh (2)

Countries

United States (21)  ·  Egypt (11)  ·  Canada (4)  ·  China (4)  ·  Denmark (4)  ·  France (4)  ·  India (2)  ·  Israel (2)  ·  Nigeria (2)  ·  Pakistan (2)  ·  Singapore (2)  ·  Spain (2)  ·  Tanzania (2)  ·  United Kingdom (2)  ·  Zambia (2)

Top investigators

Helen Colquhoun, MD (2)  ·  Yariv Yogev, professor (2)  ·  AbdelGany M Hassan (1)  ·  Ahmed N Afifi, MD (1)  ·  Ahmed N Shaker, MD (1)  ·  Alexander J Butwick, F.R.C.A. (1)  ·  Alicia V Aleman, MD (1)  ·  Amgad E. Abou-Gamrah, Ass.Prof. (1)  ·  Amon Agaba, PhD (1)  ·  Amy Brenner (1)  ·  Anne J. Wikkelsoe, MD (1)  ·  Antonio Ragusa, Dr (1)  ·  Arash Afshari, MD (1)  ·  Ban Leong Sng, FANZCA (1)

Results publications

PMID 33232518, PMID 39162220, PMID 30177236, PMID 33181049, PMID 11207490, PMID 17567419, PMID 19846212, PMID 20056720, PMID 20187965, PMID 20455694, PMID 20884642, PMID 21381158, PMID 22064874, PMID 22565291, PMID 22805300, PMID 22869824, PMID 23215909, PMID 23460682, PMID 23487258, PMID 24880136, PMID 25369200, PMID 25549051, PMID 25586727, PMID 25588587, PMID 26059839, PMID 27188698, PMID 27350226, PMID 28317031, PMID 28413832, PMID 28456509, PMID 28796940, PMID 29558233, PMID 29743045, PMID 29879947, PMID 29945633, PMID 30134136, PMID 30322584, PMID 30514326, PMID 30594227, PMID 30606246, PMID 31962259, PMID 32005192, PMID 32492040, PMID 33169839, PMID 33913639, PMID 34190962, PMID 35038612, PMID 35303924, PMID 36271352, PMID 36724109

NIH funding

2017 (2), 2008 (1), 2009 (1), 2014 (1), D43TW005492 (1), D43TW009343 (1), R01MH053735 (1), R01MH071825 (1), R21MD017396 (1), U24HD092094 (1)